Capsule Summary Slidesets

Share

Program Content

Activities

  • DSMM XIII: Rd + ASCT + R vs Cont Rd
    DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2022

    Expires: December 11, 2023

  • Phase II GEM-CESAR
    Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

  • MonumenTAL-1: Talquetamab
    MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

  • KarMMa-2 Cohort 2a
    Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

  • Mezigdomide + Dex in RR MM
    Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

  • IFM 2017-03: Dara + Len Without Dex
    IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

  • Myeloma XI: Len Maintenance
    Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

  • ASCENT: Dara-KRd in SMM
    ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

  • UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM
    UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

  • Ide-Cel After BCMA-TT
    Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

Provided by

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen